济民健康(603222) - 2025 Q2 - 季度业绩预告

Current Period Performance Forecast The company forecasts a net loss for H1 2025, with attributable net profit expected between -55 million and -46 million yuan, a stark reversal from the prior year's profit H1 2025 Performance Forecast vs. Prior Year | Indicator | H1 2025 (Forecast) | H1 2024 (Prior Year) | | :--- | :--- | :--- | | Net Profit Attributable to Parent Company (Million Yuan) | -55 to -46 | 25.4450 | | Net Profit Attributable to Parent Company (Excluding Non-Recurring Items) (Million Yuan) | -55 to -46 | 24.4007 | - This performance forecast is a preliminary estimate based on the company's operating conditions and has not been audited by a certified public accounting firm[4] Prior Period Operating Performance In H1 2024, the company reported a net profit of 25.4450 million yuan attributable to the parent company, with earnings per share of 0.05 yuan H1 2024 Performance Review | Indicator | Amount | | :--- | :--- | | Net Profit Attributable to Parent Company (Million Yuan) | 25.4450 | | Net Profit Attributable to Parent Company (Excluding Non-Recurring Items) (Million Yuan) | 24.4007 | | Earnings Per Share (Yuan) | 0.05 | Main Reasons for Current Period Loss Forecast The H1 2025 loss is primarily due to declining export sales from US tariffs, a severe impact on domestic sales from the "He Qinghong Private Seal Incident," and significant inventory impairment provisions Impact of US Tariffs: Decline in Export Business US tariff policies severely impacted the export business of safety syringes, resulting in significant declines in both revenue and gross profit - Export revenue for safety syringes declined by approximately 40%[7] - Export gross profit for safety syringes declined by approximately 82%[7] Impact of “He Qinghong Private Seal Incident”: Decline in Domestic Business The "He Qinghong Private Seal Incident" severely disrupted domestic sales channels, causing a sharp decline in revenue for pre-filled catheter flush syringes and safety syringes - Sales revenue for pre-filled catheter flush syringes and safety syringes (domestic sales) declined by approximately 92% compared to the prior year due to this incident[8] Provision for Inventory Impairment Due to challenging market conditions and prudence, an additional 20 million yuan inventory impairment provision was made for pre-filled catheter flush syringes and safety syringes, worsening the current loss - An additional inventory impairment provision of approximately 20 million yuan was made for existing pre-filled catheter flush syringes and safety syringes[9] Risk Warning and Other Notes This performance forecast is preliminary and unaudited, with final financial data subject to the official H1 2025 report, urging investors to consider associated risks - This performance forecast is a preliminary estimate, unaudited by an accounting firm, and the company anticipates no significant uncertainties affecting its accuracy[10] - The specific and accurate financial data will be based on the company's officially disclosed H1 2025 report[11]